New Novartis MS pill racks up 10,000 U.S. users

Novartis' new Gilenya multiple sclerosis pill is "doing very well" in the U.S., with more than 10,000 patients using the treatment, the Swiss drugmaker's head of development has said. Report

Suggested Articles

A $300M pandemic ad campaign may be falling apart as HHS employees push back, celebrities balk and agency brass push a rushed timeline, Politico says.

With a pack of drugmakers angling for COVID-19 vaccine approvals in the coming months, the task of global distribution is more important than ever. Wi

"We have a chance to improve our reputation if we deliver on our purpose to find solutions responsibly," GSK CEO Emma Walmsley said.